Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Liquid Biopsy in Male Genital Tract: Testis Tumor Publisher



Rashedi S1 ; Yasseri AF1 ; Khoshchehreh M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Pathology, University of California, Los Angeles, CA, United States

Source: Liquid Biopsy in Urogenital Cancers and its Clinical Utility Published:2022


Abstract

Testis cancer is the most common solid tumor in the male population aged 15-35, which accounts for 20% of diagnosed malignancies in this age-group. The conventional serum tumor markers such as α-fetoprotein (AFP), β-subunit of human chorionic gonadotropin (β-hCG), and lactate dehydrogenase (LDH) for testicular cancer are increased in only 60% of the testicular germ cell tumors (GCTs). Moreover, these tumor markers do not show a rise in patients with pure teratoma. Therefore, other tumor markers are needed to improve diagnostic evaluation, prognosis evaluation, and recurrence monitoring in patients with testicular tumors to facilitate clinical treatment. Several clinical studies have implied the prognostic significance of detecting circulating tumor cells (CTCs), micro-RNAs, cell-free DNA, and epigenetic factors in these patients. Some of these studies have encouraging results. Even though liquid biopsy is a new entity in testicular cancer, it barges its way into diagnosing, treating, and monitoring GCTs. To date, serum micro-RNAs, especially miR-371-3p, have manifested promising results in these fields in numerous experiments. However, further investigations would be crucial to find novel markers and establish their role in various clinical aspects of patients with testicular cancers, more importantly, GCTs. © 2022 Elsevier Inc. All rights reserved.
1. Liquid Biopsy As a New Tool for Diagnosis, Monitoring, and Personalized Medicine in Urogenital Cancers, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
3. Liquid Biopsy in Bladder Tumors, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
4. Liquid Biopsy in Pediatric Urogenital Tumors, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
5. Liquid Biopsy in Thyroid Cancer: New Insight, International Journal of Hematology-Oncology and Stem Cell Research (2018)
6. Liquid Biopsy in Kidney Tumor, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
7. Overview of Liquid Biopsy, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
Experts (# of related papers)
Other Related Docs
9. Liquid Biopsy in Female Genital Tract (Ovarian Cancer, Endometrial Tumor, and Cervical Tumor), Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
10. Altered Mir-223 Expression in Sputum for Diagnosis of Non-Small Cell Lung Cancer, Avicenna Journal of Medical Biotechnology (2017)
12. Exosomes and Micrornas in Biomedical Science, Synthesis Lectures on Biomedical Engineering (2022)
13. Regenerative Medicine in Urology, Stem Cells in Urology (2020)
14. The Importance of Personalized Medicine in Urological Cancers, Journal of Diabetes and Metabolic Disorders (2021)
15. Circulating Tumor Dna (Ctdna) in the Era of Personalized Cancer Therapy, Journal of Diabetes and Metabolic Disorders (2018)
20. Introduction, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
21. Cancer Stem Cells, Stem Cells in Urology (2020)
22. Introduction, Stem Cells in Urology (2020)